Oxford Immunotec Announces Availability of the T-SPOT.CMV

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Oxford Immunotec Announces Availability of the T-SPOT.CMV Test in the United States

OXFORD, U.K. and MARLBOROUGH, Mass., March 31, 2015 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD ), a global, commercial-stage diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions, today announced the availability in the United States of a new test that measures the strength of a patient's cellular immune response to cytomegalovirus (CMV). This T-SPOT ® . CMV test is available as a Laboratory Developed Test from the Company's CLIA-certified and CAP accredited service laboratory.

"We are pleased to provide physicians the T-SPOT. CMV test earlier than our previously announced timeline," said Dr. Peter Wrighton-Smith, Chief Executive Officer of Oxford Immunotec. "While we are enthusiastic about the potential clinical utility and economic value that the T-SPOT. CMV test may provide in transplant medicine, we are taking a measured approach to market introduction as we await the results of our PROTECT and REACT clinical trials. We continue to expect full commercial launch in the second half of 2016."

T cell immunity against CMV is a factor in controlling viral latency and susceptibility to CMV disease. CMV can affect individuals with weaknesses in their T cell response and it is therefore an important and common cause of morbidity and mortality in solid organ and hematopoietic stem cell transplant recipients. The T-SPOT. CMV test measures the strength of T cell responses to CMV specific antigens. The T-SPOT. CMV test has the potential to assist clinicians with monitoring anti-viral prophylaxis and evaluating patients at risk from CMV disease.

The T-SPOT. CMV test leverages Oxford Immunotec's proprietary T-SPOT technology platform. The new test will be performed at Oxford Diagnostic Laboratories in Memphis, TN, where validation was performed. The test results will be available to customers within two days of receipt of a whole blood sample. The T-SPOT. CMV test builds on Oxford Immunotec's capabilities in T cell measurement technology, and is the first in a series of planned new products intended to help transplant patients and physicians manage immune regulated conditions.

The T-SPOT. CMV test is pending approval in California, New York and Florida.

About Oxford Immunotec

Oxford Immunotec Global PLC is a global, commercial-stage diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions. The Company's first product is the T-SPOT. TB test, which is used to test for tuberculosis infection. The T-SPOT. TB  test has been approved for sale in over 50 countries, including the United States, where it has received pre-market approval from the Food and Drug Administration, Europe, where it has obtained a CE mark, as well as Japan and China. The T-SPOT. CMV test is the Company's second product and the first of three products we intend to launch for the transplantation market. Overall, the Company has six active development programs, each of which leverages our T cell and innate immune measuring technology. The Company is headquartered near Oxford, UK and in Marlborough, MA. Additional information can be found at www.oxfordimmunotec.com .

T-SPOT and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd.

CONTACTS:

For Media Inquiries: 
Caroline Crawley
Oxford Immunotec
Tel: +44 1235 442796
ccrawley@oxfordimmunotec.com

For Investor Inquiries:
Rick Altieri
Chief Financial Officer
Oxford Immunotec
Tel: +1 (508) 573-9953
raltieri@oxfordimmunotec.com

Mark Klausner
Westwicke Partners
Tel: +1 (443) 213-0500
oxfordimmunotec@westwicke.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Epic Blue Puts $50,000 of Marketing Work to Use Locally

Updated Category News Views 61

A $50,000 pile of donated know-how can look soft on a spreadsheet, until you remember how often a small nonprofit or early-stage outfit gets ignored because it cannot afford someone to sharpen its message. Epic Blue Marketing, a women-owned firm based in Jackson, Michigan, says it provided that amount in donated and reduced-rate marketing, communications and public...

Continue Reading
Dallas College Recognition Signals Workforce Value

Updated Category News Views 49

Economic mobility rarely arrives with brass bands, but it can show up in a community-college ranking. Dallas College has landed on TIME and Statista's inaugural America’s Best Community Colleges 2027 list, one of 250 schools selected from roughly 1,100 nationwide. For a region that keeps talking about talent pipelines, this is a useful piece of outside validation—not...

Continue Reading
Align Wagner Collection Tests Men's Footwear Depth

Updated Category News Views 57

Three pairs of shoes are not a revolution, but they can expose whether a young brand has its footing. Align, established in 2025 by H.H. Brown, is rolling out the Wagner collection for Fall-Winter 2026 with a waterproof boot, a penny loafer and a lace-up oxford. That is a sensible little arsenal, not some overstuffed catalog dreamed up by a marketing committee that has...

Continue Reading
Lennar's 6.73% Slide Puts Disclosure Claims in Focus

Updated Category News Views 12

A homebuilder can survive ugly margins; murky demand signals are another beast entirely. Lennar is staring at a securities class action after a bruising run of disclosures and market reactions, and the central issue is not whether housing got tougher. Everybody with a pulse knew rates were squeezing buyers. The issue is whether NYSE:LEN gave investors a sufficiently clear...

Continue Reading
Faex Health Adds Ebola and H. pylori AI Screening Tools

Updated Category News Views 82

A smartphone pointed at a toilet is an awkward place to hunt for medical progress, yet Faex Health is making a serious attempt to turn that daily evidence into an early-warning tool. The company has added investigational pre-screening capabilities for Ebola virus disease and Helicobacter pylori, or H. pylori, bringing its internally validated panel to 18 gastrointestinal...

Continue Reading
Duetti, CesiumAstro, and a Busy NYSE Capital Morning

Updated Category News Views 78

Three very different piles of money are jamming up the November 20 NYSE slate, and that contrast is the whole point. Private music catalogs, space-and-defense communications, and a new stock-and-bond ETF do not belong in the same bucket. Yet all three are competing for investor attention before the opening bell, alongside Danaos Corporation's 20th listing anniversary....

Continue Reading
ASA’s 2026 Grants Push Dermatology Into New Terrain

Updated Category News Views 80

Thirteen Small Bets With Serious Human Stakes Skin science rarely gets the splashy headlines, yet it touches a staggering number of people and carries some very stubborn unanswered questions. American Skin Association’s 2026 grant class puts 13 awards across skin cancer and dermatologic disease, with a noticeable willingness to follow newer clinical terrain rather than...

Continue Reading
Nansha's Trade Pitch Has Numbers, but Questions Remain

Updated Category News Views 84

A Chilean cherry spending 22 days at sea can tell an investor plenty about where Guangzhou's Nansha District wants to sit in Asia-Pacific commerce. Not glamorous, no. But trade infrastructure rarely is until volumes pile up, routes deepen, and somebody else finds they cannot easily replicate the network. Nansha is using the expected 33rd APEC Economic Leaders' Meeting in...

Continue Reading
Mason Adds Nonprofit Expertise to Institutional Bench

Updated Category News Views 110

Endowment committees rarely need more noise; they need somebody who has actually sat through the uncomfortable votes. Mason Investment Advisory Services has hired Rebecca “Becky” Farnsworth, CFA, as a senior investment consultant, and this looks like a practical addition rather than the usual chest-thumping personnel announcement. Her stated focus will be...

Continue Reading
Oatly’s $4.13 Tender Offer Is a Legal Detour, Not a Sale

Updated Category News Views 100

A $4.13 cash offer trading against a $7.17 close is the sort of thing that makes investors squint hard, and Verlinvest is practically waving a flag telling them why. This is not a conventional attempt to buy Oatly Group AB. It is a technical tender offer built to satisfy Swedish takeover rules while Verlinvest buys out its joint-venture partner’s interest in Oatly’s...

Continue Reading

Top 5 Most Recently Viewed Articles

DatChat Receives Mexican Patent for Enhanced Privacy Solutions

Updated Category News Views 157

DatChat's Latest Patent Achievement New Brunswick, NJ - DatChat, Inc. (NASDAQ: DATS), a leading company in secure messaging and social media, has exciting news to share. Recently, the Mexican Patent office issued a Notice of Allowance for DatChat's patent application titled "Systems and Methods of Transforming Electronic Content." This development follows the company...

Continue Reading
Flora Growth Partners with Canopy to Enhance Cannabis Access

Updated Category News Views 111

Flora Growth Enters the Australian Medical Cannabis Market Flora Growth Corp (NASDAQ: FLGC) has recently taken a significant step into the Australian medical cannabis arena through its strategic partnership with Canopy Growth Corp (NASDAQ: CGC). A distribution agreement has been signed, allowing Flora's subsidiary, Australian Vaporizers, to handle the distribution of...

Continue Reading
Digital Brands Group Sets Public Offering of 11.36 Million Units

Updated Category News Views 167

Digital Brands Group Projects Strong Growth with New Offering Digital Brands Group, Inc. (OTC PINK: DBGI), a unique entity known for curating luxury lifestyle brands, has recently made headlines with their announcement regarding a public offering. This initiative, which involves an impressive volume of 11.36 million units, is set to make waves in the market. Details of...

Continue Reading
Unraveling Solana's Remarkable Rise From $11 to $166

Updated Category News Views 154

Unraveling Solana's Remarkable Rise From $11 to $166 Solana (SOL), a cryptocurrency that emerged in March 2020, has astonished investors with its dramatic increase in value. It has risen more than 15 times its initial value, predominantly bolstered by a vibrant ecosystem that has flourished around various meme coins. Jim Cramer’s Warning In 2022, Jim Cramer, a prominent...

Continue Reading
LO3 Capital Revolutionizes Travel Services with CCRA Deal

Updated Category News Views 189

LO3 Capital Makes Strategic Investment in CCRA International LO3 Capital, a dynamic private investment firm, is making waves with its recent senior debt investment in CCRA International, Inc. This relationship is pivotal for CCRA, a technology-driven travel services platform, as it progresses towards acquiring ABC Global Services. This acquisition is set to form one of...

Continue Reading